This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Beth Rogozinski
CEO at Oncoustics

Profile

Beth Rogozinski, CEO, Oncoustics Beth Rogozinski is CEO at Oncoustics, an innovative AI diagnostics company that is creating low cost, non-invasive solutions for the detection and surveillance for diseases of the liver, kidney and pancreas. As a serial entrepreneur, technology professional, and business strategist, Beth has produced and published more than a dozen products for health and wellness. As Chief Product Officer at Pear Therapeutics, she led the development of Pear’s first clinical products and the product team submission of the De Novo 510k to the FDA. Pear’s ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic. Beth is an advisor to many start-ups and accelerators and has consulted with international biopharma and venture groups around digital health investments. Beth is an advisor and mentor in the UCSF Health Hub, at Columbia’s HIT Lab and has written and published on digital therapeutics and tech innovations. She is excited to bring to life AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need.

Agenda Sessions

  • The digital healthcare revolution

    On Demand